ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
3.290
-0.250 (-7.06%)
At close: Dec 5, 2025, 4:00 PM EST
3.390
+0.100 (3.04%)
After-hours: Dec 5, 2025, 7:06 PM EST
ADC Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ADC Therapeutics stock have an average target of 7.60, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 131.00% from the current stock price of 3.29.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 16, 2025.
Analyst Ratings
The average analyst rating for ADC Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +112.77% | Oct 16, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +203.95% | Aug 13, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $8 → $5 | Buy | Maintains | $8 → $5 | +51.98% | Jun 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $7 → $10 | Strong Buy | Maintains | $7 → $10 | +203.95% | Jun 13, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +143.16% | May 15, 2025 |
Financial Forecast
Revenue This Year
78.18M
from 70.84M
Increased by 10.36%
Revenue Next Year
81.20M
from 78.18M
Increased by 3.87%
EPS This Year
-1.44
from -1.62
EPS Next Year
-1.13
from -1.44
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 81.5M | 96.6M | ||||
| Avg | 78.2M | 81.2M | ||||
| Low | 74.3M | 67.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 15.0% | 23.6% | ||||
| Avg | 10.4% | 3.9% | ||||
| Low | 4.8% | -13.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.41 | -0.88 | |
| Avg | -1.44 | -1.13 | |
| Low | -1.45 | -1.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.